All In Biotech

Drug Trial Radar · NCT07869836

BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy

A Phase 3 Open-Label, Randomized Controlled Trial of T-bren (BL M07D1) vs. Platinum-based Chemotherapy in Patients With HER2 Expressing Metastatic Urothelial Cancer With Disease Progression on or After Anti-PD-(L)1-based Therapy

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 520 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

520

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Dec 2028

Study completion Dec 2029

Sponsor

Lead sponsor
SystImmune Inc.Industry
Sponsor type
Industry
First posted
Oct 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of the study is to evaluate the efficacy and safety of T-bren in participants with HER2 expressing metastatic UC with progression on or after anti-PD-(L)1-based therapy.

Conditions

  • Urothelial Cancer
  • Metastatic Urothelial Cancer
  • Bladder Cancer
  • Bladder Cancer (BC)
  • Bladder (Urothelial, Transitional Cell) Cancer
  • Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable
  • Bladder Ca
  • Bladder Cancer Recurrent
  • Bladder Cancer Stage IV
  • Urothelial Carcinoma Bladder
  • Urothelial Carcinoma Recurrent
  • Urothelial Carcinoma of the Urinary Bladder

Interventions

  • T-Bren, Dose level 1Drug

    T-bren: Administered intravenously on day 1 of each 21-day cycle

  • T-bren, Dose level 2Drug

    TBren administered intravenously on day 1 of each 21-day cycle

  • Gemcitabine + Platinum Based Chemotherapy (Cisplatin or Carboplatin)Drug

    Gemcitabine administered intravenously on Day 1 and Day 8 of each 21-day cycle and Cisplatin or Carboplatin administered intravenously on Day 1 of each 21-day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: Approximately 5 years

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Central Georgia Cancer Center

    Macon, Georgia · Recruiting

  • (AOR) Hawaii Cancer Care

    ‘Aiea, Hawaii · Recruiting

  • (AOR) Hematology Oncology Associates of Fredericksburg

    Fredericksburg, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.